1,2,3,4-tetrahydro-1,3-dioxa-2-phospha-naphthalen-2-oxide | 4304-27-2

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 1,2,3,4-tetrahydro-1,3-dioxa-2-phospha-naphthalen-2-oxide
• CAS: 4304-27-2
• 化学式: C₇H₇O₃P
• 分子量: 170.105
• InChiKey: QZODLRPXYFKURU-UHFFFAOYSA-N

物化性质

• 沸点：
  275.4±33.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  11.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.53
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  水杨醇 在 水 、 三乙胺 、 三氯化磷 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 1,2,3,4-tetrahydro-1,3-dioxa-2-phospha-naphthalen-2-oxide
  参考文献：
  名称：

  Lithium phosphonate umpolung catalysts: Do fluoro substituents increase the catalytic activity?

  摘要：

  氟化和非氟化膦酸酯被用作锂膦酸酯催化的十字苯并联偶反应的前催化剂。令人惊讶的是，与非氟化系统相比，观察到氟化前催化剂的催化活性降低。此外，六、七和九元环催化剂的环大小似乎并不关键于它们的催化活性。

  DOI：

  10.3762/bjoc.7.138

文献信息

• CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：Fujifilm Corporation

  公开号：US20210155644A1

  公开（公告）日：2021-05-27

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1] (in the formula, R 1 represents a hydrogen atom, a halogen atom, an amino group which may be substituted, a monocyclic nitrogen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a monocyclic nitrogen- and oxygen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; and X represents an oxygen atom or a sulfur atom) or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂具有优异药效的化合物，以及一种抗腺病毒药剂。本发明提供了一种包括由通式[1]表示的化合物的抗腺病毒药剂 （在公式中，R 1 表示氢原子、卤素原子、可能被取代的氨基、可能被取代的单环氮含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的单环氮和氧含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的C 1-6 烷氧基、可能被保护的羟基等；R 2 表示氢原子或氨基保护基团；R 3 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；R 4 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；X表示氧原子或硫原子）或其盐。
• THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION
  申请人：FUJIFILM Corporation

  公开号：US20170233429A1

  公开（公告）日：2017-08-17

  Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1] (in the formula, R 1 represents a hydroxyl group which may be protected, a C 1-20 alkoxy group which may be substituted, or the like; R 2 represents a C 1-20 alkoxy group which may be substituted, a C 3-8 cycloalkoxy group which may be substituted, or the like; and R 3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.

  揭示了一种化合物和药物组合物，对抗抗对吉西他滨产生耐药性的肿瘤表现出优异的药效。具体来说，提供了一种由通用式[1]表示的硫代核苷衍生物 （在公式中，R1代表可能被保护的羟基、可能被取代的C1-20烷氧基等；R2代表可能被取代的C1-20烷氧基、可能被取代的C3-8环烷氧基等；R3代表氢原子等）或其盐。此外，提供了含有这种硫代核苷衍生物或其盐的药物组合物。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：PHARMASSET INC

  公开号：WO2012075140A1

  公开（公告）日：2012-06-07

  Disclosed herein are 2'-spiro-nucleosides of formula I and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus. Formula (I), where z is a four-or five-membered ring selected from among radicals a-o represented by de following structures (II) where * represents the point of attachment to the 2'-carbon.

  本文披露了公式I的2'-螺环核苷及其衍生物，用于治疗感染丙型肝炎病毒或登革病毒的受试者。公式(I)中，z是从以下结构(II)所代表的基团a-o中选择的四元或五元环。其中*表示连接到2'-碳的位置。
• COMPOUNDS
  申请人：DU JINFA

  公开号：US20120142626A1

  公开（公告）日：2012-06-07

  Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus.

  本文公开了2'-螺环核苷及其衍生物，用于治疗感染丙型肝炎病毒或登革热病毒的患者。
• 2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C
  申请人：Gilead Pharmasset LLC

  公开号：EP3042910A2

  公开（公告）日：2016-07-13

  Disclosed herein are 2'-spiro-nucleosides of formula I and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus, wherein B is selected from among B2 and B3 represented by the following structures:

  本文公开了式 I 的 2'-spiro-nucleosides 及其衍生物，可用于治疗丙型肝炎病毒或登革热病毒感染者、 其中 B 选自以下结构代表的 B2 和 B3：